AGC Biologics to expand CDMO capabilities in Japan with new $350M Yokohama site
The facility, slated to be GMP-ready in 2027, will house one of Japan’s largest single-use bioreactor systems for mammalian production, according to the company.
Read the full article on the original site.
Read Full Article